As a matter of fact, NKG2D-CAR-transduced NK cells demonstrated higher killing activity and efficacy in targeting Multiple Myeloma cells towards NKG2D-CAR-transduced T cells [25]. This evidence concerns the gene KLRK1 and plasma cell myeloma.